DE69604009D1 - Stabile flüssige Zusammensetzung enthaltend Urateoxidase und lyophilizierte Zusammensetzung für seine Herstellung - Google Patents

Stabile flüssige Zusammensetzung enthaltend Urateoxidase und lyophilizierte Zusammensetzung für seine Herstellung

Info

Publication number
DE69604009D1
DE69604009D1 DE69604009T DE69604009T DE69604009D1 DE 69604009 D1 DE69604009 D1 DE 69604009D1 DE 69604009 T DE69604009 T DE 69604009T DE 69604009 T DE69604009 T DE 69604009T DE 69604009 D1 DE69604009 D1 DE 69604009D1
Authority
DE
Germany
Prior art keywords
urate oxidase
manufacture
stable liquid
composition containing
liquid composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69604009T
Other languages
English (en)
Other versions
DE69604009T2 (de
Inventor
Claude Aleman
Alain Bayol
Thierry Breul
Patrice Dupin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
SANOFI PARIS
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOFI PARIS, Sanofi SA filed Critical SANOFI PARIS
Publication of DE69604009D1 publication Critical patent/DE69604009D1/de
Application granted granted Critical
Publication of DE69604009T2 publication Critical patent/DE69604009T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
DE69604009T 1995-05-11 1996-05-09 Stabile flüssige Zusammensetzung enthaltend Urateoxidase und lyophilizierte Zusammensetzung für seine Herstellung Expired - Lifetime DE69604009T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (2)

Publication Number Publication Date
DE69604009D1 true DE69604009D1 (de) 1999-10-07
DE69604009T2 DE69604009T2 (de) 2000-04-06

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69604009T Expired - Lifetime DE69604009T2 (de) 1995-05-11 1996-05-09 Stabile flüssige Zusammensetzung enthaltend Urateoxidase und lyophilizierte Zusammensetzung für seine Herstellung

Country Status (24)

Country Link
US (1) US5811096A (de)
EP (1) EP0742013B1 (de)
JP (1) JP2950775B2 (de)
CN (1) CN1090972C (de)
AT (1) ATE183925T1 (de)
AU (1) AU710288B2 (de)
BR (1) BR1100337A (de)
CA (1) CA2175971C (de)
CZ (1) CZ290799B6 (de)
DE (1) DE69604009T2 (de)
DK (1) DK0742013T3 (de)
EA (1) EA000024B1 (de)
ES (1) ES2137635T3 (de)
FR (1) FR2733914B1 (de)
GR (1) GR3031896T3 (de)
HU (1) HU225147B1 (de)
IL (1) IL118171A (de)
NO (1) NO315261B1 (de)
NZ (1) NZ286554A (de)
PL (1) PL184135B1 (de)
SG (1) SG42355A1 (de)
SI (1) SI0742013T1 (de)
TW (1) TW420614B (de)
ZA (1) ZA963683B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
BRPI0409532B8 (pt) * 2003-04-02 2021-05-25 Ares Trading Sa composição farmacêutica líquida, artigo de fabricação, método de fabricação de composição farmacêutica e método de fabricação de artigo de fabricação
SI1638595T1 (sl) * 2003-06-20 2013-04-30 Ares Trading S.A. Liofilizirane formulacije fsh/lh
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP2947145A1 (de) 2005-04-11 2015-11-25 Crealta Pharmaceuticals LLC Variante formen von uratoxidase und verwendung davon
SG161248A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
JP2019511531A (ja) * 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置

Also Published As

Publication number Publication date
CN1147961A (zh) 1997-04-23
NO961915D0 (no) 1996-05-10
NO315261B1 (no) 2003-08-11
PL184135B1 (pl) 2002-09-30
TW420614B (en) 2001-02-01
JPH0925242A (ja) 1997-01-28
ES2137635T3 (es) 1999-12-16
FR2733914B1 (fr) 1997-08-01
HUP9601241A2 (en) 1997-04-28
ZA963683B (en) 1997-11-10
HU9601241D0 (en) 1996-07-29
ATE183925T1 (de) 1999-09-15
CN1090972C (zh) 2002-09-18
JP2950775B2 (ja) 1999-09-20
DK0742013T3 (da) 2000-03-06
MX9601756A (es) 1997-07-31
EA199600024A2 (ru) 1996-12-30
EP0742013B1 (de) 1999-09-01
HU225147B1 (en) 2006-07-28
AU710288B2 (en) 1999-09-16
IL118171A (en) 2000-08-31
CA2175971A1 (en) 1996-11-12
AU5213996A (en) 1996-11-21
DE69604009T2 (de) 2000-04-06
SG42355A1 (en) 1997-08-15
BR1100337A (pt) 2000-07-25
IL118171A0 (en) 1996-09-12
CZ135096A3 (en) 1996-12-11
EP0742013A1 (de) 1996-11-13
US5811096A (en) 1998-09-22
FR2733914A1 (fr) 1996-11-15
NO961915L (no) 1996-11-12
EA000024B1 (ru) 1997-12-30
SI0742013T1 (en) 1999-12-31
EA199600024A3 (ru) 1997-03-31
NZ286554A (en) 1998-09-24
PL314147A1 (en) 1996-11-12
CZ290799B6 (cs) 2002-10-16
CA2175971C (en) 2003-12-30
GR3031896T3 (en) 2000-02-29
HUP9601241A3 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
DE69604009D1 (de) Stabile flüssige Zusammensetzung enthaltend Urateoxidase und lyophilizierte Zusammensetzung für seine Herstellung
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
WO1995007108A3 (en) Formulations for delivery of osteogenic proteins
GR3033204T3 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
FR2742989B1 (fr) Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
AU1777495A (en) Stable freeze-dried formulation comprising a protein; assay kit
NO304261B1 (no) Preparat omfattende en lipofil forbindelse
ATA186692A (de) Pharmazeutische zusammensetzung
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
DK0477143T3 (da) Farmaceutisk præparat med en ardannende virkning

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

R082 Change of representative

Ref document number: 742013

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE